Baidu
map

药械

订阅

MedSci主页 / 所有栏目 / 药械

J Clin Oncol：拉帕替尼+曲妥珠单抗单抗+AI治疗HR+HER2+转移性乳腺癌

2018-02-14 Aries 肿瘤资讯

乳腺癌HER2拉帕替尼曲妥珠单抗
关注

该研究旨在评估内分泌治疗和一线曲妥珠单抗+化疗经治的HR+HER2+绝经后乳腺癌患者，使用抗HER2双靶治疗联合AI的疗效和安全性。

该研究旨在评估内分泌治疗和一线曲妥珠单抗+化疗经治的HR+HER2+绝经后乳腺癌患者，使用抗HER2双靶治疗联合AI的疗效和安全性。患者按1：1：1随机接受拉帕替尼+曲妥珠单抗+AI或曲妥珠单抗+AI或拉帕替尼+AI，主要终点是拉帕替尼+曲妥珠单抗+AI对比曲妥珠单抗+AI的PFS，其他终点包括其他干预组的PFS，OS、总体反应率、临床获益率和安全性。结果显示双靶+AI组的PFS、临床获益率、总体反应率及OS均优于其他亚组，三组的严重不良反应时间发生率相当，双靶+AI组因不良反应终止治疗的发生率较低。因此，对于三阳晚期乳腺癌患者，抗HER2双靶治疗+AI方案可免去化疗，效率显着，毒性低。

原始出处：

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1865340, encodeId=9be0186534046, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Oct 22 20:07:00 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648117, encodeId=5126164811e0d, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Sun Jun 24 08:07:00 CST 2018, time=2018-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386363, encodeId=b63c1386363d0, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Feb 16 05:07:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441541, encodeId=95ec14415412c, content=<a href='/topic/show?id=1b785613921' target=_blank style='color:#2F92EE;'>#拉帕替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56139, encryptionId=1b785613921, topicName=拉帕替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7acb4863797, createdName=ms9474365431325850, createdTime=Fri Feb 16 05:07:00 CST 2018, time=2018-02-16, status=1, ipAttribution=)]
    2018-10-22 minlingfeng

    #Oncol#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1865340, encodeId=9be0186534046, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Oct 22 20:07:00 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648117, encodeId=5126164811e0d, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Sun Jun 24 08:07:00 CST 2018, time=2018-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386363, encodeId=b63c1386363d0, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Feb 16 05:07:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441541, encodeId=95ec14415412c, content=<a href='/topic/show?id=1b785613921' target=_blank style='color:#2F92EE;'>#拉帕替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56139, encryptionId=1b785613921, topicName=拉帕替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7acb4863797, createdName=ms9474365431325850, createdTime=Fri Feb 16 05:07:00 CST 2018, time=2018-02-16, status=1, ipAttribution=)]
    2018-06-24 linlin2320

    #曲妥珠#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1865340, encodeId=9be0186534046, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Oct 22 20:07:00 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648117, encodeId=5126164811e0d, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Sun Jun 24 08:07:00 CST 2018, time=2018-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386363, encodeId=b63c1386363d0, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Feb 16 05:07:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441541, encodeId=95ec14415412c, content=<a href='/topic/show?id=1b785613921' target=_blank style='color:#2F92EE;'>#拉帕替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56139, encryptionId=1b785613921, topicName=拉帕替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7acb4863797, createdName=ms9474365431325850, createdTime=Fri Feb 16 05:07:00 CST 2018, time=2018-02-16, status=1, ipAttribution=)]
    2018-02-16 1249842em09(暂无昵称)

    #转移性#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1865340, encodeId=9be0186534046, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Oct 22 20:07:00 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648117, encodeId=5126164811e0d, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Sun Jun 24 08:07:00 CST 2018, time=2018-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386363, encodeId=b63c1386363d0, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Feb 16 05:07:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441541, encodeId=95ec14415412c, content=<a href='/topic/show?id=1b785613921' target=_blank style='color:#2F92EE;'>#拉帕替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56139, encryptionId=1b785613921, topicName=拉帕替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7acb4863797, createdName=ms9474365431325850, createdTime=Fri Feb 16 05:07:00 CST 2018, time=2018-02-16, status=1, ipAttribution=)]
    2018-02-16 ms9474365431325850

    #拉帕替尼#

    0

相关资讯

Oncogene：昆明动物所在 miRNA 调控乳腺癌血管新生研究中取得进展

近日，中国科学院昆明动物研究所陈策实课题组在 miRNA 调控乳腺癌血管新生功能与机制研究中取得进展，研究成果以 Hypoxia induces miR-153 through the IRE1α-XBP1 pathway to fine tune the HIF1α/VEGFA axis in breast cancer angiogenesis 为题，在线发表在 Oncogene 上。该研究揭

《中国晚期乳腺癌维持治疗专家共识》（2018）要点

乳腺癌是女性最常见的恶性肿瘤之一。我国女性乳腺癌发病率逐年升高，每年新发患者约27万例，其中3%~8%的乳腺癌患者初诊时即为转移性。即使接受了手术及规范治疗的早期患者，仍有30%~40%会复发转移。晚期乳腺癌目前虽难以治愈，但可通过研发新型治疗药物，优化治疗模式等方法来缓解患者的临床症状，改善患者的生活质量，进一步延长患者的生存期。维持治疗的理念早在白血病治疗中被提出，而后在非小细胞肺癌和肠癌等实

Oncogenesis：伊马替尼或可靶向治疗某些雌激素受体阳性乳腺小叶浸润癌

该研究使用新的雌激素受体阳性ILC模型（BCK4）和基因表达阵列发现，BCK4细胞系和异种移植肿瘤大约200个重叠基因受到体外雌激素调节，根据通路分析显示，c-Kit通路可能成为减少雌激素诱导乳腺癌细胞增殖的靶点。

NPJ Breast Cancer：卵巢切除术显著影响绝经前雌激素受体阳性乳腺癌基因表达

该研究分析了卵巢切除术对56例绝经前雌激素受体阳性乳腺癌女性乳房切除术前两周内分泌和全基因组转录的影响。

Eur J Cancer：筛查间期检出 HER2 阳性早期乳腺癌患者预后较差，应积极治疗

该研究对病理分期T1aN0M0乳腺癌的874例50～69岁女性进行分析，并排除未接受筛查、HER2状态未知、接受曲妥珠单抗辅助治疗的患者。

2017年美国乳腺癌靶向药全新汇总

在全世界范围内，乳腺癌都是威胁女性生命健康的首要杀手，虽然经过根治性手术，以及必要的术后辅助治疗，大部分早期乳腺癌复发几率会大大降低，可达到临床治愈。

Baidu
map
Baidu
map
Baidu
map